nct_id: NCT05319730
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2022-04-08'
study_start_date: '2023-05-16'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Supportive care measures'
  - drug_name: 'Biological: Sacituzumab tirumotecan'
  - drug_name: 'Drug: Steroid Mouthwash (dexamethasone or equivalent)'
  - drug_name: 'Drug: H2 Receptor Antagonist'
  - drug_name: 'Drug: Antihistamine'
  - drug_name: 'Drug: Irinotecan'
  - drug_name: 'Drug: Dexamethasone (or equivalent)'
  - drug_name: 'Drug: Lenvatinib'
  - drug_name: 'Biological: Pembrolizumab'
  - drug_name: 'Drug: Acetaminophen (or equivalent)'
  - drug_name: 'Biological: MK-4830'
  - drug_name: 'Drug: Paclitaxel'
long_title: 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational
  Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants
  With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06):
  Substudy 06B'
last_updated: '2025-11-10'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Merck Sharp & Dohme LLC
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 230
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'The main inclusion and exclusion criteria include but are not limited to the following:'
- 'Inclusion Criteria:'
- '* Histologically or cytologically confirmed diagnosis of metastatic or locally
  advanced unresectable esophageal squamous cell carcinoma (ESCC)'
- '* Has experienced investigator documented radiographic or clinical disease progression
  on one prior line of standard therapy, that includes a platinum agent and previous
  exposure to an anti-programmed cell death 1 (PD1)/programmed cell death ligand 1
  (PD-L1) based immune oncology (IO) therapy'
- '* Has provided an archival or most recent tumor tissue sample obtained as part
  of clinical practice'
- "* Participants who have adverse events (AEs) due to previous anticancer therapies\
  \ must have recovered to \u2264Grade 1 or baseline. Participants with endocrine-related\
  \ AEs who are adequately treated with hormone replacement or participants who have\
  \ \u2264Grade 2 neuropathy are eligible"
- 'Exclude - Exclusion Criteria:'
- Exclude - * Direct invasion into adjacent organs such as the aorta or trachea
- Exclude - * Has experienced weight loss \>10% over approximately 2 months prior
  to first dose of study therapy
- Exclude - * Has history of documented severe dry eye syndrome, severe Meibomian
  gland disease and/or blepharitis, or severe corneal disease that prevents/delays
  corneal healing
- Exclude - * Has active inflammatory bowel disease requiring immunosuppressive medication
  or previous history of inflammatory bowel disease
- Exclude - * Has received an investigational agent or has used an investigational
  device within 4 weeks prior to study intervention administration
- Exclude - * Known additional malignancy that is progressing or has required active
  treatment within the past 3 years, except basal cell carcinoma of the skin, squamous
  cell carcinoma of the skin, or carcinoma in situ that has undergone potentially
  curative therapy
- Exclude - * Known active central nervous system (CNS) metastases and/or carcinomatous
  meningitis
- Exclude - * Participants with human immunodeficiency virus (HIV) with a history
  of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Exclude - * History of allogenic tissue/solid organ transplant
- Exclude - * Clinically significant cardiovascular disease within 12 months from
  first dose of study intervention
- Exclude - * Has risk for significant gastrointestinal (GI) bleeding such as a serious
  nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to allocation/randomization,
  significant bleeding disorders, vasculitis, or has had a significant bleeding episode
  from the GI tract within 12 weeks prior to allocation/randomization
short_title: A Study to Evaluate Investigational Agents With or Without Pembrolizumab
  (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to
  Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment
  (MK-3475-06B)
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Merck Sharp & Dohme LLC
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This is a Phase 1/2, multicenter, randomized, open-label umbrella platform
  study to evaluate the safety and efficacy of investigational agents with or without
  pembrolizumab and/or chemotherapy, for the treatment of participants with second
  line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed
  to PD-1/PD-L1 based treatment.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Paclitaxel or irinotecan
      arm_internal_id: 0
      arm_description: Participants receive paclitaxel 80-100 mg/m\^2 intravenously
        (IV) on Days 1, 8, and 15 every 28-day cycle until progressive disease (PD)
        or discontinuation, or irinotecan 180 mg/m\^2 IV on day 1 of every 14-day
        cycle until PD or discontinuation.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Paclitaxel'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Irinotecan'
        level_internal_id: 1
        level_suspended: N
    - arm_code: Pembrolizumab + MK-4830 + paclitaxel or irinotecan
      arm_internal_id: 1
      arm_description: Participants receive pembrolizumab 200 mg IV once every 3 weeks
        (Q3W) for up to 35 cycles (cycle=21 days) or until PD or discontinuation +
        MK-4830 800 mg IV Q3W up to 35 infusions + paclitaxel 80-100 mg/m\^2 IV on
        Days 1, 8, and 15 every 28-day cycle until PD or discontinuation or irinotecan
        180 mg/m\^2 180 mg/m\^2 on day 1 every 14-day cycle until PD or discontinuation.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Paclitaxel'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Irinotecan'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Biological: Pembrolizumab'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Biological: MK-4830'
        level_internal_id: 3
        level_suspended: N
    - arm_code: Pembrolizumab + MK-4830 + lenvatinib
      arm_internal_id: 2
      arm_description: Participants receive pembrolizumab 200 mg IV Q3W up to 35 cycles
        (cycle=21 days) until PD or discontinuation + MK-4830 800 mg IV Q3W up to
        35 infusions + lenvatinib 20 mg oral administration every day until PD or
        discontinuation.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Biological: Pembrolizumab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Biological: MK-4830'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Lenvatinib'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Sacituzumab tirumotecan 4 mg/kg
      arm_internal_id: 3
      arm_description: Participants will receive 4 mg/kg of sacituzumab tirumotecan
        via IV infusion on Days 1, 15, and 29 of each 42-day cycle until discontinuation.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Biological: Sacituzumab tirumotecan'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Antihistamine'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: H2 Receptor Antagonist'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Acetaminophen (or equivalent)'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Dexamethasone (or equivalent)'
        level_internal_id: 4
        level_suspended: N
      - level_code: '5'
        level_description: 'Drug: Steroid Mouthwash (dexamethasone or equivalent)'
        level_internal_id: 5
        level_suspended: N
      - level_code: '6'
        level_description: 'Drug: Supportive care measures'
        level_internal_id: 6
        level_suspended: N
    - arm_code: Sacituzumab tirumotecan 5 mg/kg
      arm_internal_id: 4
      arm_description: Participants will receive 5 mg/kg of sacituzumab tirumotecan
        via IV infusion on Days 1, 15, and 29 of each 42-day cycle until discontinuation.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Biological: Sacituzumab tirumotecan'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Antihistamine'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: H2 Receptor Antagonist'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Acetaminophen (or equivalent)'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Dexamethasone (or equivalent)'
        level_internal_id: 4
        level_suspended: N
      - level_code: '5'
        level_description: 'Drug: Steroid Mouthwash (dexamethasone or equivalent)'
        level_internal_id: 5
        level_suspended: N
      - level_code: '6'
        level_description: 'Drug: Supportive care measures'
        level_internal_id: 6
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Metastatic
        - Locally Advanced
        oncotree_primary_diagnosis: Esophageal Squamous Cell Carcinoma
